SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Parkin DM,Bray F,Ferlay J,Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005; 55: 74108.
  • 2
    Iro H,Waldfahrer F. Evaluation of the newly updated TNM classification of head and neck carcinoma with data from 3247 patients. Cancer. 1998; 83: 22012207.
  • 3
    Kowalski LP,Carvalho AL. Natural history of untreated head and neck cancer. Eur J Cancer. 2000; 36: 10321037.
  • 4
    Forastiere AA,Metch B,Schuller DE, et al. Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study. J Clin Oncol. 1992; 10: 12451251.
  • 5
    Schantz SP,Harrison LB,Forastiere A. Tumors of the nasal cavity and paranasal sinuses, nasopharynx, oral cavity, and oropharynx. In: DeVitaVT,HellmanSA,RosenbergSA, eds. Cancer. Principles and Practice of Oncology,6th ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 2001: 797860.
  • 6
    Leon X,Hitt R,Constenla M, et al. A retrospective analysis of the outcome of patients (pts) with recurrent or metastatic squamous cell carcinoma of the head and neck (R&M SCCHN) who are progressing while on a platinum-based palliative chemotherapy [abstract]. Proc Am Soc Oncol. 2003; 22: 502. Abstract 2022.
  • 7
    Leon X,Hitt R,Constenla M, et al. A retrospective analysis of the outcome of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck refractory to a platinum-based chemotherapy. Clin Oncol (R Coll Radiol). 2005; 17: 418424.
  • 8
    Numico G,Merlano M. Second-line treatment with docetaxel after failure of a platinum-based chemotherapy in squamous-cell head and neck cancer. Ann Oncol. 2002; 13: 331333.
  • 9
    Iop A,Cartei G,Isaia A. Vinorelbine, bleomycin and methotrexate as a salvage therapy for patients with head and neck squamous carcinoma in relapse after cisplatin/fluorouracil. Ann Oncol. 1998; 9: 225227.
  • 10
    Moroni M,Giannetta L,Gelosa G, et al. Second-line chemotherapy with bleomycin, methotrexate, and vinorelbine (BMV) for patients with squamous cell carcinoma of the head, neck and esophagus (SCC-HN&E) pretreated with a cisplatin-containing regimen: a phase II study. J Chemother. 2003; 15: 394399.
  • 11
    Arteaga C. Targeting HER1/EGFR: a molecular approach to cancer therapy. Semin Oncol. 2003; 30: 314.
  • 12
    Herbst RS,Langer CJ. Epidermal growth factor receptors as a target for cancer treatment: the emerging role of IMC-C225 in the treatment of lung and head and neck cancers. Semin Oncol. 2002; 29: 2736.
  • 13
    Ang KK,Berkey BA,Tu X, et al. Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res. 2002; 62: 73507356.
  • 14
    Christensen ME,Therkildsen MH,Hansen BL,Albeck H,Hansen GN,Bretlau P. Epidermal growth factor receptor expression on oral mucosa dysplastic epithelia and squamous cell carcinomas. Eur Arch Otorhinolaryngol. 1992; 249: 243247.
  • 15
    Grandis RJ,Melhem MF,Gooding WE, et al. Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst. 1998; 90: 799801.
  • 16
    Goldstein NI,Prewett M,Zuklys K,Rockwell P,Mendelsohn J. Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clin Cancer Res. 1995; 1: 13111318.
  • 17
    Mendelsohn J. Epidermal growth factor receptor inhibition by a monoclonal antibody as anticancer therapy. Clin Cancer Res. 1997; 3: 27032707.
  • 18
    Fan Z,Masui H,Altas I,Mendelsohn J. Blockade of epidermal growth factor receptor function by bivalent and monovalent fragments of 225 anti-epidermal growth factor receptor monoclonal antibodies. Cancer Res. 1993; 53: 43224328.
  • 19
    Li S,Schmitz KR,Jeffrey PD,Wiltzius JJ,Kussie P,Ferguson KM. Structural basis for inhibition of the epidermal growth factor receptor by cetuximab. Cancer Cell. 2005; 7: 301311.
  • 20
    Fan Z,Lu Y,Wu X,Mendelsohn J. Antibody-induced epidermal growth factor receptor dimerization mediates inhibition of autocrine proliferation of A431 squamous carcinoma cells. J Biol Chem. 1994; 269: 2759527602.
  • 21
    Robert F,Ezekiel MP,Spencer SA, et al. Phase I study of anti-epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer. J Clin Oncol. 2001; 19: 32343243.
  • 22
    Bonner JA,Harari PM,Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. 2006; 354: 567578.
  • 23
    Burtness BA,Goldwasser MA,Flood W,Mattar BI,Forastiere A. Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group Study. J Clin Oncol. 2005; 23: 86468654.
  • 24
    Bourhis J,Rivera F,Mesia R, et al. Phase I/II study of cetuximab in combination with cisplatin or carboplatin and fluorouracil in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol. 2006; 24: 28662872.
  • 25
    Vermorken JB,Mesia R,Vega E, et al. Cetuximab extends survival of patients with recurrent or metastatic SCCHN when added to first line platinum based therapy—results of a randomized phase III (EXTREME) study [abstract]. Proc Am Soc Clin Oncol. 2007; 25: 670s. Abstract 16516.
  • 26
    Trigo J,Hitt R,Koralewski P, et al. Cetuximab monotherapy is active in patients (pts) with platinum-refractory recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN): results of a phase II study [abstract]. J Clin Oncol. 2004; 22(14S). Abstract 5502.
  • 27
    Vermorken JB,Trigo J,Hitt R, et al. Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J Clin Oncol. 2007; 25: 21522155.
  • 28
    Baselga J,Trigo JM,Bourhis J, et al. Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck. J Clin Oncol. 2005; 23: 55685577.
  • 29
    Baselga J,Trigo JM,Bourhis J, et al. Cetuximab (C225) plus cisplatin/carboplatin is active in patients (pts) with recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN) progressing on a same dose and schedule platinum-based regimen [abstract]. Proc Am Soc Clin Oncol. 2002; 21. Abstract 900.
  • 30
    Herbst RS,Arquette M,Shin DM, et al. Epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck: a phase II, multicenter study. J Clin Oncol. 2005; 23: 55785587.
  • 31
    Kies MS,Arquette MA,Nabell L, et al. Final report of the efficacy and safety of the anti-epidermal growth factor antibody Erbitux (IMC-C225), in combination with cisplatin in patients with recurrent squamous cell carcinoma of the head and neck (SCCHN) refractory to cisplatin containing chemotherapy [abstract]. Proc Am Soc Clin Oncol. 2002; 21. Abstract 925.
  • 32
    Kaplan EL,Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958; 53: 457481.
  • 33
    Vermorken JB,Bourhis J,Trigo J, et al. Cetuximab (Erbitux) in recurrent/metastatic (R&M) squamous cell carcinoma of the head and neck (SCCHN) refractory to first-line platinum-based therapies [abstract]. J Clin Oncol. 2005; 23. Abstract 5505.
  • 34
    Segaert S,Tabernero J,Chosidow O, et al. The management of skin reactions in cancer patients receiving epidermal growth factor receptor targeted therapies. J Dtsch Dermatol Ges. 2005; 3: 599606.
  • 35
    Segaert S,Van Cutsem E. Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. Ann Oncol. 2005; 16: 14251433.
  • 36
    Saltz L,Kies M,Abbruzzese JL,Azarnia N,Needle M. The presence and intensity of the cetuximab-induced acne-like rash predicts increased survival in studies across multiple malignancies [abstract]. Proc Am Soc Clin Oncol. 2003; 22. Abstract 817.
  • 37
    Merlano M,Grimaldi A,Bonelli L,Tatarek R,Rosso R. Failure of second-line therapy to modify survival in relapsed squamous cell carcinoma of the head and neck. Tumori. 1985; 71: 367370.
  • 38
    Keldsen N. Cisplatin as second line chemotherapy in advanced or recurrent squamous cell carcinoma of head and neck region. Acta Oncol. 1987; 26: 357359.
  • 39
    Gebbia V,Valenza R,Testa A, et al. Methotrexate, vinblastine, epidoxorubicin, and bleomycin as second-line chemotherapy for recurrent and/or metastatic squamous cell carcinoma of the head and neck. ORL J Otorhinolaryngol Relat Spec. 1994; 56: 279282.
  • 40
    Porta C,Brugnatelli S,Patruno E, et al. Single-agent vinorelbine (VRB) as second-line treatment for advanced or recurrent squamous-cell carcinoma of the head and neck (SCCHN) [abstract]. Proc Am Soc Clin Oncol. 2001; 22. Abstract 2537.
  • 41
    Gustafson NF,Saltz L,Cunningham D,Lenz H,Humphrey R,Adegbile IA. Safety profile of cetuximab in patients with metastatic colorectal cancer [abstract]. Presented at the 2004 ASCO Gastrointestinal Cancers Symposium, SanFrancisco, California, January 22–24, 2004. Abstract 237.